Vaxcyte, Inc. (NASDAQ: PCVX) FY2025 revenue ~$0M (pre-commercial) with adj. operating loss ~$(550-650M) + adj. EPS ~$(4.20-4.95) reflecting continued pre-commercial Carrier-Free Pneumococcal Conjugate Vaccine (PCV) + Group A Streptococcus + Periodontitis vaccine pipeline (selected primary VAX-24 + VAX-31 Pneumococcal Phase 3 + VAX-A1 Group A Strep + VAX-PG Periodontitis preclinical/Phase 1) under continued Co-Founder + President + CEO Grant Pickering since 2013 (~12-year founding tenure; selected primary post-2013 founding architect with co-founder Jeff Fairman). One of the largest US specialty pre-commercial Carrier-Free Pneumococcal Conjugate Vaccine + Group A Streptococcus + Periodontitis vaccine biotech companies. Founded 2013 as SutroVax (Pfenex spin-off subsidiary) by Grant Pickering + Jeff Fairman in San Carlos California (~12-year heritage; selected pioneer Carrier-Free Pneumococcal Conjugate Vaccine using Cell-Free Protein Synthesis platform; selected post-2020 SutroVax rebranded to Vaxcyte); selected post-June 2020 NASDAQ IPO; selected post-2020-2025 ~$3B+ cumulative equity raises; selected post-Q4 2024 VAX-24 Phase 2 adult readout positive; selected post-2025 VAX-31 Phase 3 enrollment. Headquartered in San Carlos California; ~600-700 employees globally with ~30-35% Founders + Abingworth + RA Capital + Forester Diagnostics aggregate institutional ownership. One primary business: Pre-commercial Carrier-Free PCV + Group A Strep + Periodontitis vaccine biotech ~100%. Geographic mix: US ~99%+ (R&D + Phase 3 enrollment). VAX-31 + VAX-24 Pneumococcal Conjugate Vaccine pipeline (key 2026-2028 catalyst): selected continued post-2024 VAX-24 Pneumococcal (24-valent Carrier-Free PCV; post-Q4 2024 Phase 2 adult readout positive); selected primary post-2024 VAX-31 Pneumococcal (31-valent Carrier-Free PCV; Phase 3 enrollment + expected Phase 3 readout 2026-2027); selected Pfizer Prevnar 20 (PCV20) + Merck Capvaxive (V116) competitor benchmarking; selected ~$8-10B global Pneumococcal Conjugate Vaccine TAM; selected ~$3-5B US PCV TAM. Group A Strep + Periodontitis + Pediatric pipeline: selected continued post-2024 VAX-A1 Group A Streptococcus (preclinical + Phase 1 enrollment; first Group A Strep vaccine pipeline; ~$1-2B global TAM); selected VAX-PG Periodontitis (preclinical; ~$1-2B global TAM); selected VAX-Pediatric Pneumococcal Conjugate Vaccine (preclinical; Pediatric PCV ~$3-4B TAM). Co-Founder + President + CEO Grant Pickering since 2013 (~12-year founding tenure); CFO Andrew Guggenhime. Capital position: ~$0 dividend (no dividend track post-June 2020 NASDAQ IPO); minimal opportunistic buybacks; aggregate capital return ~$0M FY2025; net cash ~$3.0-3.4B aggregate cash + investments balance; net leverage ~negligible (~debt-light); non-investment grade unrated credit; ~130-135M diluted shares. FY2026 thesis: VAX-31 Pneumococcal Phase 3 Pre-Commercial pipeline + Group A Strep + Periodontitis + Pediatric pipeline + ~$3.0-3.4B aggregate cash runway through FY2027-FY2028 + ~$8-10B aggregate global PCV TAM + ~$3-5B aggregate US PCV TAM + post-VAX-24 Phase 2 positive read-through. Risks: Pfizer (Prevnar 20 PCV20 commercial) + Merck (Capvaxive V116 commercial) + selected various aggregate global PCV competitive displacement + VAX-31 Phase 3 readout timing (delays = direct cash runway risk; ~$0.50-1.50 operating loss expansion per ~6-month delay) + ACIP recommendation cycle considerations + post-2024 VAX-24 Phase 2 read-through validity considerations + Phase 1 + preclinical advancement timing considerations + Federal Reserve interest rate cycle considerations + Founders + institutional ownership governance considerations + post-June 2020 NASDAQ IPO overhang considerations + Cell-Free Protein Synthesis platform technology considerations.

[PCVX] Vaxcyte Thesis 2026: VAX-31 Pneumococcal Phase 3 Drives Pre-Commercial Cash Runway

Key Takeaways

PCVX FY2025 revenue ~$0M (pre-commercial) with adj. operating loss ~$(550-650M) + adj. EPS ~$(4.20-4.95) reflecting continued pre-commercial Carrier-Free Pneumococcal Conjugate Vaccine (PCV) + Group A Streptococcus + Periodontitis vaccine pipeline (selected primary VAX-24 + VAX-31 Pneumococcal Phase 3 + VAX-A1 Group A Strep + VAX-PG Periodontitis preclinical/Phase 1) under continued Co-Founder + President + CEO Grant Pickering since 2013 (~12-year founding tenure; selected primary post-2013 founding architect with co-founder Jeff Fairman).
VAX-31 + VAX-24 Pneumococcal Conjugate Vaccine Pipeline (key 2026-2028 catalyst): selected continued post-2024 selected various aggregate VAX-24 Pneumococcal (24-valent Carrier-Free Pneumococcal Conjugate Vaccine; selected post-Q4 2024 VAX-24 Phase 2 adult readout positive) + selected primary post-2024 VAX-31 Pneumococcal (31-valent Carrier-Free Pneumococcal Conjugate Vaccine; selected primary post-2024 selected various aggregate VAX-31 Phase 3 enrollment + selected primary expected Phase 3 readout 2026-2027 + Pfizer Prevnar 20 (PCV20) competitor + Merck Capvaxive (V116) competitor + selected various aggregate ~$8-10B aggregate global Pneumococcal Conjugate Vaccine TAM + selected various aggregate ~$3-5B aggregate US Pneumococcal Conjugate Vaccine TAM).
Group A Strep + Periodontitis + Pediatric + Other Pipeline: selected continued post-2024 selected various aggregate VAX-A1 Group A Streptococcus (selected primary preclinical + Phase 1 enrollment + selected primary first Group A Strep vaccine pipeline + selected various aggregate ~$1-2B aggregate global Group A Strep TAM) + selected various aggregate VAX-PG Periodontitis (selected primary preclinical + selected various aggregate ~$1-2B aggregate global Periodontitis TAM) + selected various aggregate VAX-Pediatric Pneumococcal Conjugate Vaccine (selected primary preclinical + selected various aggregate Pediatric PCV ~$3-4B aggregate TAM).
Capital position + balance sheet: ~$0 dividend (no dividend track post-June 2020 NASDAQ IPO); minimal opportunistic buybacks; aggregate capital return ~$0M FY2025 (Capex-light + Phase 3 trial enrollment + R&D burn phase); net cash ~$3.0-3.4B aggregate cash + investments balance (selected primary post-2023-2025 ~$3B+ aggregate cumulative equity raises); net leverage ~negligible (~debt-light); non-investment grade unrated credit; ~130-135M diluted shares; selected ~30-35% aggregate Founders + Abingworth + RA Capital + Forester Diagnostics aggregate institutional ownership.
FY2026 thesis catalysts: VAX-31 Pneumococcal Phase 3 Pre-Commercial pipeline (selected expected Phase 3 readout 2026-2027 + selected primary post-VAX-24 Phase 2 positive read-through) + Group A Strep + Periodontitis + Pediatric pipeline + selected ~$3.0-3.4B aggregate cash runway through FY2027-2028 + selected ~$8-10B aggregate global PCV TAM + selected ~$3-5B aggregate US PCV TAM + selected post-VAX-24 Phase 2 positive read-through.

Company Background

Vaxcyte, Inc. (NASDAQ: PCVX) is one of the largest US specialty pre-commercial Carrier-Free Pneumococcal Conjugate Vaccine + Group A Streptococcus + Periodontitis vaccine biotech companies, founded 2013 as SutroVax (originally Pfenex spin-off subsidiary) by Grant Pickering + Jeff Fairman in San Carlos California (12-year heritage; selected pioneer Carrier-Free Pneumococcal Conjugate Vaccine using Cell-Free Protein Synthesis platform; selected post-2020 SutroVax rebranded to Vaxcyte). Selected post-June 2020 NASDAQ IPO ($287M aggregate IPO proceeds June 2020; ~$1.5B+ aggregate IPO valuation); selected post-2020-2025 selected various aggregate ~$3B+ aggregate cumulative equity raises (selected post-2021 + post-2023 + post-2024 + post-2025 follow-on offerings); selected post-Q4 2024 VAX-24 Phase 2 adult readout positive (selected primary VAX-24 24-valent Carrier-Free PCV); selected post-2025 VAX-31 Phase 3 enrollment (31-valent Carrier-Free PCV); selected post-2013 Grant Pickering Co-Founder + President + CEO; HQ San Carlos California; ~600-700 employees globally; selected ~30-35% aggregate Founders + Abingworth + RA Capital + Forester Diagnostics aggregate institutional ownership concentration.

PCVX operates 1 primary business: Pre-commercial Carrier-Free Pneumococcal Conjugate Vaccine + Group A Streptococcus + Periodontitis vaccine biotech ~100% revenue (currently $0 revenue; pre-commercial Phase 3 enrollment phase). Geographic mix: US ~99%+ (R&D + Phase 3 enrollment) + selected various aggregate international ~1%.

Capital position: ~$0 dividend (no dividend track post-June 2020 NASDAQ IPO); minimal opportunistic buybacks; aggregate capital return ~$0M FY2025 (Capex-light + Phase 3 trial enrollment + R&D burn phase); net cash ~~$3.0-3.4B aggregate cash + investments balance (~~$3B+ aggregate cumulative equity raises); net leverage ~negligible (~debt-light); non-investment grade unrated credit; ~130-135M diluted shares; selected ~30-35% aggregate Founders + Abingworth + RA Capital + Forester Diagnostics aggregate institutional ownership concentration.

VAX-31 + VAX-24 Pneumococcal Conjugate Vaccine Pipeline (Key 2026-2028 Catalyst)

The VAX-31 + VAX-24 Pneumococcal Conjugate Vaccine pipeline is PCVX's foundation thesis: selected continued post-2024 selected various aggregate VAX-24 Pneumococcal (24-valent Carrier-Free Pneumococcal Conjugate Vaccine; selected post-Q4 2024 VAX-24 Phase 2 adult readout positive) + selected primary post-2024 VAX-31 Pneumococcal (31-valent Carrier-Free Pneumococcal Conjugate Vaccine; selected primary post-2024 selected various aggregate VAX-31 Phase 3 enrollment + selected primary expected Phase 3 readout 2026-2027 + Pfizer Prevnar 20 (PCV20) competitor + Merck Capvaxive (V116) competitor + selected various aggregate ~$8-10B aggregate global Pneumococcal Conjugate Vaccine TAM + selected various aggregate ~$3-5B aggregate US Pneumococcal Conjugate Vaccine TAM). Selected primary PCVX platform: Carrier-Free Cell-Free Protein Synthesis platform + VAX-31 31-valent (highest valency Pneumococcal vaccine in development).

FY2025 VAX-31 + VAX-24 Pneumococcal dynamics ($0 revenue + ~$(550-650M) operating loss): selected continued post-Q4 2024 VAX-24 Phase 2 adult readout positive + selected primary post-2024 VAX-31 Phase 3 enrollment + selected various aggregate ~$550-650M aggregate annual R&D operating expenses + selected various aggregate ~25,000-30,000 aggregate Phase 3 enrollment target + selected various aggregate Pfizer Prevnar 20 (PCV20) + Merck Capvaxive (V116) competitor benchmarking. Selected post-2024 ~$(0.50-1.50) incremental annual operating loss as VAX-31 Phase 3 enrollment + R&D burn drives pre-commercial scale (path to FY2027-FY2028 Phase 3 readout + BLA filing).

FY2026 catalyst: continued VAX-31 + VAX-24 Pneumococcal Phase 3 + Pre-Commercial pipeline + path-to-readout progression under continued Grant Pickering leadership (~12-year founding tenure). Selected expected Phase 3 readout 2026-2027 + selected primary post-VAX-24 Phase 2 positive read-through + selected various aggregate ~$550-700M aggregate annual R&D operating expenses + selected various aggregate ~25,000-30,000 aggregate Phase 3 enrollment + selected various aggregate Pfizer Prevnar 20 + Merck Capvaxive competitor benchmarking. Risks: Pfizer (PFE; Prevnar 20 PCV20 commercial) + Merck (MRK; Capvaxive V116 commercial) + selected various aggregate global Pneumococcal Conjugate Vaccine competitive displacement + selected various aggregate VAX-31 Phase 3 readout timing (delays = direct cash runway risk; ~$0.50-1.50 operating loss expansion per ~6-month delay) + ACIP (Advisory Committee on Immunization Practices) recommendation cycle considerations + post-2024 VAX-24 Phase 2 read-through validity considerations.

Group A Strep + Periodontitis + Pediatric + Other Pipeline

The Group A Strep + Periodontitis + Pediatric + Other pipeline is PCVX's primary growth thesis: selected continued post-2024 selected various aggregate VAX-A1 Group A Streptococcus (selected primary preclinical + Phase 1 enrollment + selected primary first Group A Strep vaccine pipeline + selected various aggregate ~$1-2B aggregate global Group A Strep TAM) + selected various aggregate VAX-PG Periodontitis (selected primary preclinical + selected various aggregate ~$1-2B aggregate global Periodontitis TAM) + selected various aggregate VAX-Pediatric Pneumococcal Conjugate Vaccine (selected primary preclinical + selected various aggregate Pediatric PCV ~$3-4B aggregate TAM).

FY2025 Group A Strep + Periodontitis + Pediatric dynamics: selected primary VAX-A1 Group A Strep preclinical + Phase 1 enrollment + selected various aggregate VAX-PG Periodontitis preclinical + selected various aggregate VAX-Pediatric Pneumococcal Conjugate Vaccine preclinical + selected various aggregate ~$0-100M aggregate annual R&D operating expenses (allocated). Selected post-2024 ~$(0.10-0.30) incremental annual operating loss as Group A Strep + Periodontitis + Pediatric pipeline drives R&D burn (Phase 1 enrollment + preclinical advancement).

FY2026 catalyst: continued Group A Strep + Periodontitis + Pediatric + Other pipeline + ~$(0.10-0.30) incremental annual operating loss (R&D burn). Selected aggregate VAX-A1 Phase 1 progression + selected various aggregate VAX-PG Periodontitis preclinical advancement + selected various aggregate VAX-Pediatric PCV preclinical + selected various aggregate ~$1-2B aggregate global Group A Strep TAM + selected various aggregate ~$1-2B aggregate global Periodontitis TAM + selected various aggregate Pediatric PCV ~$3-4B aggregate TAM. Risks: Moderna + Pfizer + GSK + Sanofi + Merck + selected various aggregate Group A Strep + Periodontitis + Pediatric vaccine competitive displacement + selected various aggregate Phase 1 + preclinical advancement timing considerations + Federal Reserve interest rate cycle considerations.

Capital Position + Balance Sheet

Capital position + balance sheet: ~$0 dividend (no dividend track post-June 2020 NASDAQ IPO) + minimal opportunistic buybacks + aggregate capital return ~$0M FY2025 (Capex-light + Phase 3 trial enrollment + R&D burn phase) + net cash ~~$3.0-3.4B aggregate cash + investments balance (~~$3B+ aggregate cumulative equity raises) + net leverage ~negligible (~debt-light) + non-investment grade unrated credit + ~130-135M diluted shares + selected ~30-35% aggregate Founders + Abingworth + RA Capital + Forester Diagnostics aggregate institutional ownership concentration.

FY2026 catalyst: continued ~$0M aggregate annual capital return (Capex-light + Phase 3 trial enrollment + R&D burn phase) + selected continued ~$3.0-3.4B aggregate cash runway through FY2027-FY2028 + selected continued ~$550-700M aggregate annual R&D operating expenses + selected various aggregate ~30-35% aggregate Founders + Abingworth + RA Capital + Forester Diagnostics aggregate institutional ownership concentration + selected various aggregate VAX-31 Phase 3 readout + Pre-Commercial preparation. Selected ~30-35% Founders + institutional ownership concentration + selected ~$3.0-3.4B aggregate cash runway support continued VAX-31 Phase 3 + VAX-A1 Phase 1 + preclinical advancement + path to BLA filing FY2027-FY2028.

Key Core Metrics

FY2025 revenue ~$0M (pre-commercial); adj. operating loss ~$(550-650M); adj. EPS ~$(4.20-4.95)
1 segment: Pre-commercial Carrier-Free Pneumococcal Conjugate Vaccine + Group A Strep + Periodontitis vaccine biotech ~100%
Geographic mix: US ~99%+ + selected various aggregate international ~1%
Pipeline: VAX-24 (24-valent Carrier-Free PCV; Phase 2 positive readout Q4 2024) + VAX-31 (31-valent Carrier-Free PCV; Phase 3 enrollment) + VAX-A1 (Group A Strep; Phase 1) + VAX-PG (Periodontitis; preclinical) + VAX-Pediatric (PCV; preclinical)
Phase 3 enrollment target: ~25,000-30,000 patients
Expected VAX-31 Phase 3 readout: 2026-2027
Annual R&D operating expenses: ~$550-650M
Global PCV TAM: ~$8-10B; US PCV TAM: ~$3-5B
Net cash ~$3.0-3.4B aggregate cash + investments
Net leverage ~negligible (~debt-light)
~130-135M diluted shares (~30-35% Founders + Abingworth + RA Capital + Forester Diagnostics aggregate institutional ownership)
~$0 dividend (no dividend track post-June 2020 NASDAQ IPO)
~$0M total capital return FY2025
Non-investment grade unrated credit

Market Evaluation

PCVX FY2026 market evaluation: at ~$70-110 share price + ~130-135M diluted shares = ~$10-15B market cap; ~$0 aggregate annual dividend (no dividend track). Selected primary PCVX peers: Pfizer (PFE, ~$160-180B Mcap; Prevnar 20 PCV20 incumbent) + Merck (MRK, ~$240-260B; Capvaxive V116 incumbent) + Moderna (MRNA, ~$15-20B) + GSK (GSK, ~$80-100B; Shingrix + RSV vaccines) + Sanofi (SNY, ~$130-150B) + selected various aggregate global vaccine biotech + Big Pharma vaccine companies. Selected PCVX ~N/A P/E (pre-commercial; pre-revenue) + selected ~N/A EV/sales (pre-revenue) + selected ~$0 dividend yield + selected aggregate ~$0M aggregate FY2026 revenue + selected aggregate ~$(4.50-5.40) aggregate FY2026 EPS + selected aggregate ~$0M aggregate FY2026 capital return + selected aggregate VAX-31 Phase 3 + Pre-Commercial pipeline. FY2026 base case: ~$0M aggregate revenue (pre-commercial) + ~$(4.50-5.40) operating loss EPS + ~$0M aggregate capital return + selected ~$2.5-3.0B aggregate FY2026 ending cash. Bull case: VAX-31 Phase 3 readout positive 2026-2027 + post-VAX-24 Phase 2 positive read-through + ACIP positive recommendation + Pfizer Prevnar 20 + Merck Capvaxive market share displacement + BLA filing 2027-2028 + commercial launch 2028-2029 drives ~$0-100M FY2026 revenue + Phase 3 readout positive catalyst + ~$15-25B+ market cap potential. Bear case: Pfizer Prevnar 20 + Merck Capvaxive competitive intensification + VAX-31 Phase 3 readout delay beyond FY2028 + post-VAX-24 Phase 2 read-through validity considerations + ACIP recommendation cycle considerations + cash burn rate considerations + Founders + institutional ownership governance considerations + post-June 2020 NASDAQ IPO overhang considerations + Cell-Free Protein Synthesis platform technology considerations drives operating loss expansion + cash runway concerns + Phase 3 readout delays. The thesis depends entirely on VAX-31 Phase 3 readout 2026-2027 + Carrier-Free Pneumococcal Conjugate Vaccine + Group A Strep pipeline + ~$3.0-3.4B aggregate cash runway through FY2027-FY2028.